ArticleTranslational cancer research2017
IDH mutational status and the immune system in gliomas: a tale of two tumors?
Article in Translational cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Review
- Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Radiosynthesis and biological evaluation of [European journal of nuclear medicine and molecular imaging · 2024Article
- The emerging role of the branched chain aminotransferases, BCATc and BCATm, for anti-tumor T-cell immunity.Immunometabolism (Cobham, Surrey) · 2023Review
- gp96 Expression in Gliomas and Its Association with Tumor Malignancy andJournal of oncology · 2022Article
- Immune Profiling of Syngeneic Murine and Patient GBMs for Effective Translation of Immunotherapies.Cells · 2021Review
- Tumor-Agnostic Treatment for Cancer: When How is Better than Where.Clinical drug investigation · 2020Review
- To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.Cellular and molecular neurobiology · 2020Review
- The Change of Soluble Programmed Cell Death-Ligand 1 in Glioma Patients Receiving Radiotherapy and Its Impact on Clinical Outcomes.Frontiers in immunology · 2020Article
- Current and Future Trends on Diagnosis and Prognosis of Glioblastoma: From Molecular Biology to Proteomics.Cells · 2019Review
- (R)-2-hydroxyglutarate drives immune quiescence in the tumor microenvironment of IDH-mutant gliomas.Translational cancer research · 2019Article
- Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.JCI insight · 2018Article
- An insight into the molecular genetics of a uveal melanoma patient cohort.Journal of cancer research and clinical oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.